While guidelines endorse the use of antidiabetic agents with cardiovascular and renal benefits (e.g., SGLT2 inhibitors, GLP-1a), this synchronization with BP targets as part of structured BP management pillars is not formalized in most hypertension guidelines. This evidence concerns the gene SLC5A2 and Hypertension.